news

CUPERTINO, Calif., Aug 27, 2008 /PRNewswire-FirstCall via COMTEX News Network/ — DURECT Corporation (Nasdaq: DRRX) today reported that Pain Therapeutics (Nasdaq: PTIE), its licensee, has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for an abuse-resistant opioid pain drug candidate based on DURECT’s patented ORADUR(TM) technology. This is […]

CUPERTINO, Calif., Aug. 12 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that the US Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) of REMOXY(R) and granted Priority Review. The FDA typically grants Priority Review to drug candidates that have the potential to demonstrate significant improvements compared to marketed products. The

CUPERTINO, Calif., Aug. 5 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended June 30, 2008. Total revenues were $6.3 million for the three months ended June 30, 2008, compared to $13.4 million for the same period in 2007. Net loss for the three months ended June 30, 2008

CUPERTINO, Calif., July 30 /PRNewswire-FirstCall/ — In conjunction with DURECT Corporation’s (Nasdaq: DRRX) second quarter 2008 financial results press release, you are invited to listen to the conference call that will be broadcast live over the Internet on Wednesday, August 6, 2008 at 9:00 a.m. EDT (6:00 a.m. PDT). (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO) A live audio webcast

CUPERTINO, CA, June 30, 2008 / PRNewswire-First Call via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced today that the US Food and Drug Administration (FDA) has granted to DURECT orphan drug designation for bupivacaine for relief of persistent pain associated with post-herpetic neuralgia (PHN). Bupivacaine is the active pharmaceutical ingredient in ELADUR™, DURECT’s investigational transdermal

CUPERTINO, Calif., June 17 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that the remaining $23.6 million in 6.25% Convertible Notes had been exchanged by the holders at their maturity date into approximately 7.5 million shares, per the original terms of the indenture. As a result, DURECT now has approximately 81.8 million shares of common

CUPERTINO, Calif., June 10 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that a New Drug Application (NDA) for Remoxy(TM) (ORADUR(TM)-based oxycodone) has been submitted to the U.S. Food and Drug Administration (FDA). Remoxy, an investigational drug, is a long acting oral formulation of oxycodone intended to treat moderate to severe pain. Based on DURECT’s

CUPERTINO, Calif., June 6 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that management is scheduled to present at three upcoming life sciences conferences in New York, NY. — Needham & Company’s Biotechnology and Medical Technology Conference on Thursday, June 12th at 11:30 a.m. EDT. — Leerink Swann’s Pain Roundtable Conference, on Monday, June 23rd

CUPERTINO, Calif., May 21 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the 2008 UBS Global Generic and Specialty Pharmaceuticals Conference being held at the Waldorf Hilton Hotel in London. Matthew J. Hogan, Chief Financial Officer, will be presenting at the conference on May 28th at 4:00 p.m. British Time

CUPERTINO, Calif., May 7 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended March 31, 2008. Total revenues were $6.4 million for the three months ended March 31, 2008, compared to $5.7 million for the same period in 2007. Net loss for the three months ended March 31, 2008